Background. A wealth of evidence obtained using mouse models indicates that CD4 +
INTRODUCTION
Colorectal cancer (CRC) is the fourth most commonly diagnosed malignant disease with an estimated 1 million new cases and over 500 000 deaths each year worldwide [1] . The current management of patients with CRC revolves around excision of the primary tumor and the local lymph nodes and the selective use of 5-fluorouracil (5FU; inhibits thymidylate synthase) based chemotherapy [2] . Recent advances in preoperative imaging, surgical technique and the use of neo-adjuvant chemotherapy have improved outcomes, but colorectal cancer remains the second leading cause of death from cancer in Western countries with 40-50% of patients who undergo a potentially curative operation, undergoing relapse or death from metastatic disease.
Clinico-pathological staging of the disease strongly correlates with prognosis. Interestingly, improved clinical outcome is also associated with the presence of tumor-infiltrating lymphocytes (TILs), particularly if the lymphocytes invade the glandular elements of the tumor [3, 4] . This suggests that anti-tumor immune responses can impinge on the growth of the primary tumor, and may have an important role in controlling metastatic disease. Indirect evidence for the importance of the immune response in cancer patients is the epidemiological association in some populations between an increased incidence of tumors and immunosuppression post organ transplantation [5] .
Much interest has recently arisen in the role of a naturally occurring population of CD4 + CD25 + regulatory T cells (Treg), characterized by expression of the forked-head transcription factor FOXP3, and increased levels of the surface markers CD45RO, CTLA-4, and GITR [6, 7, 8] . Treg have been shown to control self-antigen specific responses in the periphery, and hence may play a role in controlling anti-tumor immune responses. Several groups including our own, have demonstrated that depletion of Treg promotes the generation of anti-tumor immune responses and tumor rejection in murine models (reviewed in [9] ). There is evidence to suggest that these protective responses target both tumor-specific antigens as well as shared tumor antigens [10, 11] .
More recently, several studies have observed an increased frequency of CD4
+

CD25
+ T cells in the peripheral blood of patients with various types of cancer, although the majority of these studies did not confirm that these were Treg by staining for FOXP3 (reviewed in [9] ). The presence of FOXP3 + Treg within the TILs of ovarian cancer has, however, been identified as an independent risk factor for poorer prognosis. Furthermore, after purification from tumor ascites, these Treg were shown to suppress Her2-specific T cell responses in vitro [12] .
The human onco-fetal antigen, 5T4, is a 72kDa leucine-rich membrane glycoprotein which is expressed at high levels on the placenta and also on a wide range of human carcinomas including colorectal, gastric, renal and ovarian but rarely on normal tissues [13, 14, 15, 16, 17, 18] . In this study we tested the hypothesis that Treg develop in CRC patients that suppress 5T4-specific immune responses. Samples from patients with CRC or IBD, and healthy controls were examined to address three questions: is the frequency of Treg (CD25 hi CD4 + FOXP3 + T cells) increased in blood or lymph nodes from patients with CRC; can anti-tumor T cell responses to 5T4 be identified in CRC patients; and do Treg impinge on these anti-tumor immune responses?
METHODS
Sample groups
CRC patients were identified from multi-disciplinary team meetings with the first presentation of an adenocarcinoma and no reported distant metastases on cross sectional imaging (TNM stage I-III; Duke's stage A-C). IBD patients (ulcerative colitis or Crohn's disease) attending clinic or undergoing elective surgical resection were recruited to the study. Local ethical committee approval was granted for the study by the Bro Taf Local Research Ethics Committee.
Antigens
Purified protein derivative (PPD) (Statens Serum Institut, Denmark), hemaglutinin (HA) was a kind gift from Dr John Skehel (NIMR, Mill Hill), 5T4 was produced as described previously [19] (Oxford Biomedica). All antigens were used at a final concentration of 1 mg/ml.
Purification of lymphocytes
30-50 ml of blood was drawn from patients or controls and heparinized (10 U/ml). PBMCs were extracted by centrifugation over Lymphoprep (Axis-Shield, Oslo, Norway). The cells were washed twice in RPMI before further use. Lymph nodes were dissected from fresh specimens within 30 minutes of surgery, washed in RPMI, mashed through a sterile cell strainer and collected by centrifugation.
Flow cytometric analysis of lymphocytes from blood and lymph nodes
Samples were stained with fluorescently-labeled antibodies to CD4 (clone RPA-T4), CD25 (clone M-A251), CD45RO (clone UCHL1) and CTLA4 (clone BNI3) (BD Pharmingen), CD4 (clone S3.5) (Caltag) and CD25 (clone 4E3) (Miltenyi Biotec). All staining was performed in phosphate buffered saline (PBS), 2.5% FCS, 5 mM EDTA and intracellular staining was performed using the cytofix, cytoperm kit (BD Pharmingen). FOXP3 staining was performed using the FITC anti-human FOXP3 staining kit (clone PCH101) (71-5776 eBioscience). Lymphocytes were gated on forward and side scatter profiles. All flow cytometry was performed on a BD FacsCalibur and analyzed using the Summit v3.1 analysis program (build 839 Dakocytomation, Fort Collins, Colorado).
CD4
+ CD25 hi add-back experiments 
IFN-c ELISPOT assays
Antibodies were obtained from Mabtech (Natka, Sweden) and the ELISPOT was developed using the alkaline phosphatase substrate kit from Bio-Rad (Hercules, California). The effect of Treg depletion on antigen-specific IFN-c production was assessed in parallel assays. CD25 hi cells were depleted using magnetic separation with MACs CD25 microbeads (Miltenyi Biotec, Germany). Briefly, 1.5610 7 PBMC were incubated with 15 ml of anti-CD25 coated beads in total reaction volume of 150 ml of buffer (16PBS, 0.5% BSA, 5 mM EDTA) at 4uC for 15 min. Excess beads were washed off and the PBMC were run down an MS column. The column was washed with 361 ml washes in buffer. The efficacy of depletion was confirmed by flow cytometry. Assays were set up using either 3.5610 5 undepleted or CD25 hidepleted cells in RPMI 1640 supplemented with 5% heat-treated FCS, 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM Lglutamine and 1 mM sodium pyruvate per well of a polymerbacked 96-well filtration plate (MAIP-S-4510) (Millipore, Moslheim, France) in a total reaction volume of 100 ml/well. The concentrations of antibodies used and washing steps were according to the manufacturer's instructions, all antibody incubations were with 50 ml/well. The method has been previously described [20] . PPD, HA and 5T4 were tested in duplicate wells, having been added to a final concentration of 1 mg/ml, and compared with control wells with no protein. The plate was incubated at 37uC, 5% CO 2 for 18 h. Activated T cells were enumerated at the single-cell level by counting the number of spots per well using an automated ELISPOT reader (Cadama). Responders were identified as having at least 5 spot-forming cells (sfc) per 10 6 PBMC, after subtraction of the background, and an increase of at least 50% above background.
Statistical analysis
Flow cytometric data was analyzed using the unpaired student's ttest (GraphPad Prism version 2.0 (GraphPad software). The proportion of cancer patients and healthy controls mounting a response to 5T4 was compared using a closed form method for comparing differences and calculating confidence intervals [21] .
RESULTS
Defining the human Treg population
Using the strict gating parameters reported recently [8] , Treg were identified as CD4 positive cells with brighter CD25 staining than that of the CD4-negative population (Fig 1a) . 
CD25
2 T cells and, as reported by others, this suppression was dose-dependent [8, 22, 23] (Figure 1c ).
CRC patients have increased numbers of Treg in peripheral blood
The Treg were phenotypically defined as outlined above. Figure 2a shows the frequencies of Treg in the PBMCs of CRC patients (n = 12, age range 58-80 years) compared with age-matched healthy controls (n = 11, age range 48-93 years) and patients with inflammatory bowel disease (n = 22, age range 19-80 years). In all groups, the frequency of Treg was less than 2% of CD4 + T cells. However, the mean frequency in CRC patients (1.13%) was significantly increased compared with the control groups (IBD patients 0.56%, healthy controls 0.46%). There was no significant difference in the frequency of Treg in healthy controls and IBD patients.
CRC patients have increased numbers of Treg in mesenteric lymph nodes
Obtaining control lymph nodes from subjects with no abdominal disease was not possible. IBD patients offer a colonic disease control group to the CRC patients, the latter also often demonstrating areas of inflammation around the tumor. Furthermore, the results from PBMCs did not demonstrate a significant alteration in the frequencies of Treg in patients with IBD compared with healthy controls. Hence, we considered it reasonable to use mesenteric lymph nodes obtained from IBD patients undergoing surgery as a control group in which to examine Treg in secondary lymphoid tissue.
Fresh lymph nodes were obtained from the surgically resected specimens and prepared as outlined in methods. The frequencies of Treg in mesenteric lymph nodes obtained from CRC patients (n = 8), and IBD patients (n = 7) were compared (Figure 2b ). CRC patients again showed a significant increase in the frequency of Treg, reflecting the increase already described in peripheral blood. The lymph node-derived CD25
hi Treg had the same phenotype to those found in blood (data not shown). No difference was observed in the overall proportion of CD4 + or CD8 + T cells (data not shown). 
Patients with non-metastatic CRC demonstrate vigorous CD4
+ T cell responses to recall antigens PBMCs were purified from CRC patients (n = 14) prior to surgery and the specific CD4 + T cell response to the control recall antigens PPD and HA measured by IFN-c release. These results were compared with healthy age-matched controls (n = 11) (Figure 3 ). CD4 and CD8 depletion experiments confirmed that these were CD4 + T cell responses (data not shown). There was no evidence that the patients were immunosuppressed; all subjects responded to at least one antigen. Cell proliferation was also assessed in parallel experiments as a measure of T cell activation, and again no evidence of immunosuppression was found pre-operatively (data not shown).
Treg have a marked effect on anti-tumor immune responses in the blood of patients with CRC
A series of assays were performed on CRC patients (n = 14) and agematched controls (n = 11) to determine whether removal of CD25 hi cells altered the immune response to recall antigens and the tumorassociated antigen 5T4. We optimized an isolation system designed specifically to deplete only the CD25 hi cells from our samples as outlined in methods (Figure 4a ). Freshly-isolated PBMCs were used in ex vivo IFN-c ELISPOT assays as outlined above to determine responses to the recall antigens and the tumor antigen 5T4, before and after depletion of Treg. On the whole, depletion of Treg uncovered some responses to recall antigens in CRC patients and controls (Figure 4b ). However, in the case of the tumor associated antigen 5T4, there was a striking difference between controls and CRC patients. A 5T4-specific ex vivo response was found in 1/11 of the healthy controls and depletion of Treg enhanced this response. Whilst depletion of Treg augmented the 5T4-specific response in 1/ 14 of the CRC patients, depletion of this population led to the unmasking of a 5T4 response in 5/14 of the patients tested (95% Confidence Interval for paired differences is 20.83 to 20.22 revealing a significant difference in 5T4 responses between CRC patients and healthy controls). These data suggest that Treg are suppressing anti-5T4 immune responses specifically in patients with colorectal cancer. These six patients who demonstrated enhanced 5T4 responses had similar Treg frequencies in peripheral blood (range 0.82-2.35% mean 1.14%) to the frequencies measured in the entire CRC population (mean 1.13%). While IFN-c-release, measured directly ex vivo, enabled anti-5T4 responses to be detected, we did not find vigorous proliferative responses to 5T4 in either CRC patients or controls. However, with several rounds of restimulation and the addition of IL-2, we have grown out HLA-DRrestricted 5T4-specific lines (data not shown).
DISCUSSION
We compared the frequency of carefully defined CD4 + CD25 + FOXP3 + regulatory T cells (Treg) in CRC patients with healthy age-matched controls and IBD patients. CRC patients have an increased frequency of Treg and there is evidence that these Treg target anti-tumor immune responses.
We assessed whether enhanced numbers of Treg in CRC patients correlated with general immunosuppression. A combination of IFN-c ELISPOT assays and proliferation assays to monitor responses to the recall antigens PPD and HA, demonstrated equally robust responses in CRC patients and healthy controls, indicating that immune responses to non-tumor antigens are unimpaired in CRC patients.
The pattern of immune reactivity was strikingly different between CRC patients and healthy controls when immune responses to the tumor-associated onco-fetal antigen, 5T4, were 5 cells/well) with PPD (top graph), HA (middle graph) or 5T4 (lower graph). The number of responders is shown for each antigen. In each case, the percentage on the left is the frequency of responders that increased after Treg depletion (Increase), the percentage in the middle is the frequency of non-responders that had a response after depletion (New Response) and on the right the frequency of responders that showed a decrease or no change in response after Treg depletion (Decrease/NC). The 95% Confidence Interval for paired differences of proportions between patients and controls is 20.83 to 20.22 revealing a significant difference for 5T4 responses. (C) The 6 CRC patients with responses to 5T4 are shown in more detail. The bars represent the spot-forming cells/10 6 PBMC after subtraction of background spots, whole PBMC (light grey) and CD25
hi -depleted PBMC (dark grey). Responses were observed only in CD25 hi -depleted PBMC of patients 1-5, whilst a response was observed in both PBMC populations from patient 6. In all assays, wells were set up in duplicate. doi:10.1371/journal.pone.0000129.g004
compared. 5T4-specific responses were observed in a proportion of healthy controls, but these responses were largely unaltered by Treg depletion. In contrast, a 5T4-specific response was detected in more than a third of the CRC patients only after removal of Treg, suggesting that the Treg in CRC patients suppress the tumor-specific immune response. This group of CRC patients who demonstrated anti-5T4 responses after Treg depletion appeared to have similar Treg frequencies compared to the overall CRC group, although larger studies will be required to confirm this. Since 5T4-responses were not unmasked by Treg depletion in healthy controls, these data also indicate that Treg cells capable of suppressing 5T4-specific responses develop in response to the tumor. The precise mechanism through which this occurs is unclear at present, but it is possible that the cytokine milieu within the tumor promotes the generation of Treg recognizing tumorassociated antigens. Recent reports indicate a role for TGFb in the expansion of Treg [24, 25] . In a rodent tumor model it has been shown that only dendritic cells (DCs) from tumor-bearing but not tumor-free animals promote proliferation of Treg. Interestingly DCs from tumor-free animals could expand Treg, but only if preincubated with tumor cell supernatants. These effects could be inhibited in vitro using anti-TGFb antibodies [26] . Collectively, these data suggest that Treg require both a tumor antigen-specific stimulation and cytokines, such as TGFb in order to proliferate and suppress anti-tumor immune responses.
5T4 is an attractive candidate for tumor vaccines as it is expressed in many epithelial tumors. However, this study suggests that Treg recognize the antigen and possibly play a role in suppressing anti-tumor responses, presumably to the detriment of the individual. Two other studies have demonstrated that Treg recognize tumor antigens (LAGE-1 and ARTC-1) in subjects with melanoma [27, 28] . It is important to ensure that vaccine strategies using tumor-associated antigens do not boost the regulatory arm of the immune system thereby inhibiting potential anti-tumor immunity. One approach may be to deplete Treg before vaccination, as recently demonstrated for renal cell carcinoma [29] . It will be of great interest therefore to determine in future studies whether such a strategy will result in measurable clinical responses in CRC patients.
